Trelegy Ellipta vs Xolair
A side-by-side look at two respiratory medications advertised on TV. Informational only — not medical advice.
| US Trelegy Ellipta | US Xolair | |
|---|---|---|
| Generic name | fluticasone/umeclidinium/vilanterol | omalizumab |
| Drug class | Inhaled Corticosteroid + LAMA + LABA | Anti-IgE Monoclonal Antibody |
| Treats | COPD, asthma | Allergic asthma, chronic hives, food allergy |
| Category | Respiratory | Respiratory |
| Manufacturer | GSK | Genentech/Novartis |
| Year approved | 2017 | 2003 |
| FDA warning | No boxed warning | Black box warning |
| Est. TV ad spend | $200M | $95M |
| Common side effects | Thrush, Respiratory infections, Headache, Cough | Anaphylaxis (severe allergic reaction), Injection site reactions, Joint pain, Headache |
Trelegy Ellipta
Frequently asked questions
Is Trelegy Ellipta or Xolair better?
Neither is universally "better." Trelegy Ellipta (fluticasone/umeclidinium/vilanterol) and Xolair (omalizumab) are both used for respiratory, but the right choice depends on your medical history, insurance and your doctor's guidance. This comparison is informational only.
What's the difference between Trelegy Ellipta and Xolair?
Trelegy Ellipta is a Inhaled Corticosteroid + LAMA + LABA made by GSK, while Xolair is a Anti-IgE Monoclonal Antibody made by Genentech/Novartis. See the table above for a side-by-side breakdown.
Which one spends more on TV ads?
Trelegy Ellipta has the larger estimated TV advertising budget of the two.